Send a Tweet
Most Popular Choices
Share on Facebook 38 Share on Twitter Printer Friendly Page More Sharing
Exclusive to OpEd News:
General News    H3'ed 9/26/17

How Pharma Got a Quarter of the Population on Antidepressants

By       (Page 1 of 1 pages)   3 comments, In Series: Pharma
Message Martha Rosenberg
Become a Fan
  (84 fans)

From the debut of Prozac, in 1988, ten years before direct-to-consumer (DTC) drug advertising, one of the top performing drug categories was depression drugs. In fact the discovery that people with real life problems with their job, the economy and their family would term it "depression" sailed Pharma through the 1990s and 2000s. Unlike drugs like Valium and Librium which were taken as needed and which the new antidepressants replaced (because anxiety was now "really depression" according to Pharma messaging) the new antidepressants were taken every day, for years. Ka-ching.

Ten years after DTC advertising began, the number of Americans on antidepressants had already doubled to 27 million or 10 percent of the population (though almost 73 percent had no psychiatric diagnoses). Today as much as 25 percent of some U.S. demographics are on antidepressants. So many people are now on antidepressants, waterways themselves are swimming with the drugs from wastewater and fish are actually "on Prozac."

The weight gain, sexual dysfunction and bone thinning/fractures linked to antidepressants have been well publicized. But a 2010 JAMA article suggested that in most cases antidepressants don't even work. Other research suggests the drugs only work for a short time----though people are kept on them for years and even decades. (SSRI antidepressants also can trigger extreme and bizarre violence including mass shootings, knife attacks, suicide and even self-immolation.)

Faced with drugs that never work, stop working or patients who do not have depression to begin with, Pharma has rolled out a lucrative "add-on" marketing scheme. "Approximately 2 out of 3 people being treated for depression still have unresolved symptoms," it says. Pharma loves add-on campaigns because they triple its profits and few ask why they should take the first drug if it is not working. For example 100 pills of the brand name add-on drug Abilify cost $1,644 and 100 pills of the brand name add-on drug Invega cost $1,789. That's enough to make you depressed.

Add-on depression drugs triples Pharma profits
Add-on depression drugs triples Pharma profits
(Image by Martha Rosenberg)
  Details   DMCA

Other Ways To Sell Antidepressants

Pharma has other methods to prop up its depression franchise. If your first expensive drug followed by your second expensive drug doesn't work, maybe you have "treatment resistant depression!" Who's to say you don't? There is no blood test for depression. Let's add a third and fourth drug.

There is another trick to keep the antidepressant boat afloat. Before direct-to-consumer drug advertising, depression was considered to be a self-limiting disease----neither a lifelong condition or progressive. But now, Pharma, on the basis of no credible research, says depression is "progressive." Don't wait----you'll get worse says Pharma's unabashed scare campaign.

Here is how Vladimir Maletic, MD who served on Eli Lilly's Speaker's Bureau, puts it. "Depressive episodes become more easily triggered over time. As the number of major depressive episodes increase, the risk for subsequent episodes is predicted more from the number of prior episodes and less from the occurrence of a recent life stress." Does anyone need to be told that Eli Lilly makes a lot of antidepressants?

There is one more rung in Pharma's scheme of selling drugs that often don't work for a disease people often don't have. Programs for the poor. As Pharma's drug prices go up, it rolls out patient assistance programs or coupons to dodge the accusation of harming the poor. Yet the compassion pricing is merely public relations and cost shifting. Pharma still gets it five and six digit drugs paid for by taxpayers and by the premiums of the privately insured. Pharma's depression profits

Valuable 2   Must Read 1   Supported 1  
Rate It | View Ratings

Martha Rosenberg Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
   (Opens new browser window)

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

It's the Cymbalta Stupid

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too

To View Comments or Join the Conversation:

Tell A Friend